Table 4.
Acquisition of carriage of Clostridium difficile, ESBL, and MRSA organisms
|
Levofloxacin group |
Placebo group |
|||||
|---|---|---|---|---|---|---|
| C difficile | ESBL | MRSA | C difficile | ESBL | MRSA | |
| Present at baseline (785 stool, 928 nasal samples) | 1 | 19 | 5 | 5 | 37 | 9 |
| Week 4 (706 stool, 805 nasal samples) | 4 | 8 | 0 | 3 | 11 | 4 |
| Week 8 (662 stool, 759 nasal samples) | 0 | 5 | 1 | 2 | 7 | 1 |
| Week 12 (634 stool, 719 nasal samples) | 3 | 3 | 1 | 2 | 7 | 2 |
| Week 16 (593 stool, 650 nasal samples) | 4 | 9 | 2 | 1 | 5 | 0 |
| Total new acquisitions (2595 stool, 2933 nasal samples) | 11 | 25 | 4 | 8 | 30 | 7 |
ESBL=extended-spectrum β-lactamase. MRSA=methicillin-resistant Staphylococcus aureus.